BAMCO Inc
ADMS

BAMCO Inc’s Adamas Pharmaceuticals ADMS Stock Holding History

BAMCO Inc’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-78,200
Closed -$1.57M – 394
2018
Q3 		$1.57M Sell
78,200
-131,984
-63% -$3.1M 0.01% 296
2018
Q2 		$5.43M Sell
210,184
-12,382
-6% -$343K 0.02% 228
2018
Q1 		$5.32M Buy
222,566
+99,366
+81% +$3.13M 0.02% 226
2017
Q4 		$4.17M Buy
123,200
+20,000
+19% +$558K 0.02% 250
2017
Q3 		$2.19M Hold
103,200
– – 0.01% 270
2017
Q2 		$1.8M Buy
103,200
+32,272
+45% +$534K 0.01% 275
2017
Q1 		$1.24M Buy
70,928
+31,928
+82% +$544K 0.01% 292
2016
Q4 		$659K Buy
39,000
+24,500
+169% +$379K ﹤0.01% 298
2016
Q3 		$238K Buy
+14,500
New +$220K ﹤0.01% 297

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

BAMCO Inc's ADMS Position: Q4 2018 in Review

BAMCO Inc sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 78,200 shares — an estimated $1.57M sold.

BAMCO Inc first reported a position in ADMS in Q3 2016 and held it in 9 quarters. The position peaked at $5.43M in Q2 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • BAMCO Inc reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BAMCO Inc sold 78,200 Adamas Pharmaceuticals shares in Q4 2018, an estimated $1.57M.
  • BAMCO Inc first reported a position in Adamas Pharmaceuticals in Q3 2016 and held it in 9 quarters.
  • BAMCO Inc's Adamas Pharmaceuticals position peaked at $5.43M in Q2 2018.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on BAMCO Inc's 13F filing for Q4 2018, filed 14 Feb 2019.